Insider transactions

EDGAR

GENERATION BIO CO.

Transactions reported by directors, officers and 10% owners on SEC Forms 3, 4 and 5, read from each filing’s XML. Codes and their wording are the SEC’s own.

A Form 4 is due within two business days of the transaction, so the most recent trades may not be filed yet.

Window: transactions dated on or after 2025-11-21.

Open-market purchases (code P)
0 transactions, — shares
Open-market sales (code S)
0 transactions, — shares

Totals add the filed transactions listed; they are counts of what was reported, not a measure of direction.

Showing 1–50 of 116

Insider transactions, newest first, as filed on SEC Forms 3, 4 and 5
DateReporting ownerCodeAcquired or disposedSharesPrice per share, as filedValue (derived)Shares owned afterDirect or indirectRule 10b5-1 boxNotesSource
2026-02-09 Filed 2026-02-09Howze Yalonda Officer: INTERIM CEO AND PRESIDENT
U

Disposition pursuant to a tender of shares in a change of control transaction

Common Stock
Disposed (D)3,759——0Direct (D) No
F1, F2
  • F1 Pursuant to the terms of that certain Agreement and Plan of Merger (the Merger Agreement), by and among Generation Bio. Co. (the Issuer), XOMA Royalty Corporation (Parent) and Parent's wholly-owned subsidiary, XRA 7 Corp. (Merger Sub), dated as of December 15, 2025, the shares (the Shares) of common stock, par value $0.0001 per share, of the Issuer (the Common Stock) that were tendered to Merger Sub prior to the expiration time of the offer were exchanged for (i) a purchase price of $4.2913 per Share to the stockholders in cash, without interest and less any applicable tax withholding (the Cash Amount), plus (ii) one non-tradeable contingent value right per Share (the CVR),
  • F2 (continued from footnote 1) which represents the right to receive certain contingent payments in cash in accordance with the terms and subject to the conditions of a contingent value rights agreement entered into by Parent and the rights agent, with an estimated maximum contingent consideration amount of $25.01 per CVR (the Cash Amount plus one CVR, collectively, the Offer Price). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Merger Sub merged with and into the Issuer, effective as of February 9, 2026 (the Effective Time), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent.
Open filing 0001104659-26-012190 Read from the filing’s XML Dispute this row
2026-02-09 Filed 2026-02-09Howze Yalonda Officer: INTERIM CEO AND PRESIDENT
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (right to buy) — underlying Common Stock (10,710) — exercise price 39.70
Disposed (D)10,710——0Direct (D) No
F3
  • F3 Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration.
Open filing 0001104659-26-012190 Read from the filing’s XML Dispute this row
2026-02-09 Filed 2026-02-09Howze Yalonda Officer: INTERIM CEO AND PRESIDENT
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (right to buy) — underlying Common Stock (11,883) — exercise price 18.60
Disposed (D)11,883——0Direct (D) No
F3
  • F3 Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration.
Open filing 0001104659-26-012190 Read from the filing’s XML Dispute this row
2026-02-09 Filed 2026-02-09Howze Yalonda Officer: INTERIM CEO AND PRESIDENT
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (right to buy) — underlying Common Stock (25,102) — exercise price 9.255
Disposed (D)25,102——0Direct (D) No
F3
  • F3 Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration.
Open filing 0001104659-26-012190 Read from the filing’s XML Dispute this row
2026-02-09 Filed 2026-02-09Howze Yalonda Officer: INTERIM CEO AND PRESIDENT
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (right to buy) — underlying Common Stock (7,630) — exercise price 13.90
Disposed (D)7,630——0Direct (D) No
F3
  • F3 Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration.
Open filing 0001104659-26-012190 Read from the filing’s XML Dispute this row
2026-02-09 Filed 2026-02-09Appelhans Dannielle Director
U

Disposition pursuant to a tender of shares in a change of control transaction

Common Stock
Disposed (D)1,263——0Direct (D) No
F1, F2
  • F1 Pursuant to the terms of that certain Agreement and Plan of Merger (the Merger Agreement), by and among Generation Bio. Co. (the Issuer), XOMA Royalty Corporation (Parent) and Parent's wholly-owned subsidiary, XRA 7 Corp. (Merger Sub), dated as of December 15, 2025, the shares (the Shares) of common stock, par value $0.0001 per share, of the Issuer (the Common Stock) that were tendered to Merger Sub prior to the expiration time of the offer were exchanged for (i) a purchase price of $4.2913 per Share to the stockholders in cash, without interest and less any applicable tax withholding (the Cash Amount), plus (ii) one non-tradeable contingent value right per Share (the CVR),
  • F2 (continued from footnote 1) which represents the right to receive certain contingent payments in cash in accordance with the terms and subject to the conditions of a contingent value rights agreement entered into by Parent and the rights agent, with an estimated maximum contingent consideration amount of $25.01 per CVR (the Cash Amount plus one CVR, collectively, the Offer Price). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Merger Sub merged with and into the Issuer, effective as of February 9, 2026 (the Effective Time), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent.
Open filing 0001104659-26-012182 Read from the filing’s XML Dispute this row
2026-02-09 Filed 2026-02-09Appelhans Dannielle Director
U

Disposition pursuant to a tender of shares in a change of control transaction

Common Stock
Disposed (D)736——0Indirect (I) By SpouseNo
F1, F2
  • F1 Pursuant to the terms of that certain Agreement and Plan of Merger (the Merger Agreement), by and among Generation Bio. Co. (the Issuer), XOMA Royalty Corporation (Parent) and Parent's wholly-owned subsidiary, XRA 7 Corp. (Merger Sub), dated as of December 15, 2025, the shares (the Shares) of common stock, par value $0.0001 per share, of the Issuer (the Common Stock) that were tendered to Merger Sub prior to the expiration time of the offer were exchanged for (i) a purchase price of $4.2913 per Share to the stockholders in cash, without interest and less any applicable tax withholding (the Cash Amount), plus (ii) one non-tradeable contingent value right per Share (the CVR),
  • F2 (continued from footnote 1) which represents the right to receive certain contingent payments in cash in accordance with the terms and subject to the conditions of a contingent value rights agreement entered into by Parent and the rights agent, with an estimated maximum contingent consideration amount of $25.01 per CVR (the Cash Amount plus one CVR, collectively, the Offer Price). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Merger Sub merged with and into the Issuer, effective as of February 9, 2026 (the Effective Time), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent.
Open filing 0001104659-26-012182 Read from the filing’s XML Dispute this row
2026-02-09 Filed 2026-02-09Appelhans Dannielle Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (right to buy) — underlying Common Stock (3,000) — exercise price 3.874
Disposed (D)3,000——0Direct (D) No
F3
  • F3 Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock (Issuer Option) that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was less than the Cash Amount (each, an In-The-Money Option), became fully vested and was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product obtained by multiplying (x) the excess of the Cash Amount over the exercise price per share of Common Stock underlying such In-the-Money Option at the Effective Time by (y) the number of shares of Common Stock underlying such In-the-Money Option at the Effective Time.
Open filing 0001104659-26-012182 Read from the filing’s XML Dispute this row
2026-02-09 Filed 2026-02-09Appelhans Dannielle Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (right to buy) — underlying Common Stock (3,840) — exercise price 71.80
Disposed (D)3,840——0Direct (D) No
F4
  • F4 Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration.
Open filing 0001104659-26-012182 Read from the filing’s XML Dispute this row
2026-02-09 Filed 2026-02-09Appelhans Dannielle Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (right to buy) — underlying Common Stock (2,500) — exercise price 48.30
Disposed (D)2,500——0Direct (D) No
F4
  • F4 Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration.
Open filing 0001104659-26-012182 Read from the filing’s XML Dispute this row
2026-02-09 Filed 2026-02-09Appelhans Dannielle Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (right to buy) — underlying Common Stock (6,000) — exercise price 33.20
Disposed (D)6,000——0Direct (D) No
F4
  • F4 Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration.
Open filing 0001104659-26-012182 Read from the filing’s XML Dispute this row
2026-02-09 Filed 2026-02-09Conway Kevin John Officer: CHIEF FINANCIAL OFFICER
U

Disposition pursuant to a tender of shares in a change of control transaction

Common Stock
Disposed (D)2,072——0Direct (D) No
F1, F2
  • F1 Pursuant to the terms of that certain Agreement and Plan of Merger (the Merger Agreement), by and among Generation Bio. Co. (the Issuer), XOMA Royalty Corporation (Parent) and Parent's wholly-owned subsidiary, XRA 7 Corp. (Merger Sub), dated as of December 15, 2025, the shares (the Shares) of common stock, par value $0.0001 per share, of the Issuer (the Common Stock) that were tendered to Merger Sub prior to the expiration time of the Offer were exchanged for (i) a purchase price of $4.2913 per Share to the stockholders in cash, without interest and less any applicable tax withholding (the Cash Amount), plus (ii) one non-tradeable contingent value right per Share (the CVR),
  • F2 (continued from footnote 1) which represents the right to receive certain contingent payments in cash in accordance with the terms and subject to the conditions of a contingent value rights agreement entered into by Parent and the rights agent, with an estimated maximum contingent consideration amount of $25.01 per CVR (the Cash Amount plus one CVR, collectively, the Offer Price). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Merger Sub merged with and into the Issuer, effective as of February 9, 2026 (the Effective Time), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent.
Open filing 0001104659-26-012188 Read from the filing’s XML Dispute this row
2026-02-09 Filed 2026-02-09Conway Kevin John Officer: CHIEF FINANCIAL OFFICER
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (right to buy) — underlying Common Stock (1,192) — exercise price 63.587
Disposed (D)1,192——0Direct (D) No
F3
  • F3 Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration.
Open filing 0001104659-26-012188 Read from the filing’s XML Dispute this row
2026-02-09 Filed 2026-02-09Conway Kevin John Officer: CHIEF FINANCIAL OFFICER
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (right to buy) — underlying Common Stock (283) — exercise price 51.576
Disposed (D)283——0Direct (D) No
F3
  • F3 Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration.
Open filing 0001104659-26-012188 Read from the filing’s XML Dispute this row
2026-02-09 Filed 2026-02-09Conway Kevin John Officer: CHIEF FINANCIAL OFFICER
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (right to buy) — underlying Common Stock (1,061) — exercise price 190.00
Disposed (D)1,061——0Direct (D) No
F3
  • F3 Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration.
Open filing 0001104659-26-012188 Read from the filing’s XML Dispute this row
2026-02-09 Filed 2026-02-09Conway Kevin John Officer: CHIEF FINANCIAL OFFICER
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (right to buy) — underlying Common Stock (621) — exercise price 302.50
Disposed (D)621——0Direct (D) No
F3
  • F3 Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration.
Open filing 0001104659-26-012188 Read from the filing’s XML Dispute this row
2026-02-09 Filed 2026-02-09Conway Kevin John Officer: CHIEF FINANCIAL OFFICER
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (right to buy) — underlying Common Stock (1,399) — exercise price 316.90
Disposed (D)1,399——0Direct (D) No
F3
  • F3 Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration.
Open filing 0001104659-26-012188 Read from the filing’s XML Dispute this row
2026-02-09 Filed 2026-02-09Conway Kevin John Officer: CHIEF FINANCIAL OFFICER
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (right to buy) — underlying Common Stock (2,585) — exercise price 64.90
Disposed (D)2,585——0Direct (D) No
F3
  • F3 Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration.
Open filing 0001104659-26-012188 Read from the filing’s XML Dispute this row
2026-02-09 Filed 2026-02-09Conway Kevin John Officer: CHIEF FINANCIAL OFFICER
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (right to buy) — underlying Common Stock (2,800) — exercise price 81.80
Disposed (D)2,800——0Direct (D) No
F3
  • F3 Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration.
Open filing 0001104659-26-012188 Read from the filing’s XML Dispute this row
2026-02-09 Filed 2026-02-09Conway Kevin John Officer: CHIEF FINANCIAL OFFICER
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (right to buy) — underlying Common Stock (5,940) — exercise price 18.60
Disposed (D)5,940——0Direct (D) No
F3
  • F3 Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration.
Open filing 0001104659-26-012188 Read from the filing’s XML Dispute this row
2026-02-09 Filed 2026-02-09Conway Kevin John Officer: CHIEF FINANCIAL OFFICER
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (right to buy) — underlying Common Stock (200) — exercise price 42.90
Disposed (D)200——0Direct (D) No
F3
  • F3 Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration.
Open filing 0001104659-26-012188 Read from the filing’s XML Dispute this row
2026-02-09 Filed 2026-02-09Conway Kevin John Officer: CHIEF FINANCIAL OFFICER
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (right to buy) — underlying Common Stock (249) — exercise price 31.60
Disposed (D)249——0Direct (D) No
F3
  • F3 Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration.
Open filing 0001104659-26-012188 Read from the filing’s XML Dispute this row
2026-02-09 Filed 2026-02-09Conway Kevin John Officer: CHIEF FINANCIAL OFFICER
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (right to buy) — underlying Common Stock (35,525) — exercise price 9.255
Disposed (D)35,525——0Direct (D) No
F3
  • F3 Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration.
Open filing 0001104659-26-012188 Read from the filing’s XML Dispute this row
2026-02-09 Filed 2026-02-09Conway Kevin John Officer: CHIEF FINANCIAL OFFICER
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (right to buy) — underlying Common Stock (1,877) — exercise price 47.05
Disposed (D)1,877——0Direct (D) No
F3
  • F3 Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration.
Open filing 0001104659-26-012188 Read from the filing’s XML Dispute this row
2026-02-09 Filed 2026-02-09Conway Kevin John Officer: CHIEF FINANCIAL OFFICER
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (right to buy) — underlying Common Stock (550) — exercise price 50.60
Disposed (D)550——0Direct (D) No
F3
  • F3 Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration.
Open filing 0001104659-26-012188 Read from the filing’s XML Dispute this row
2026-02-09 Filed 2026-02-09Conway Kevin John Officer: CHIEF FINANCIAL OFFICER
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (right to buy) — underlying Common Stock (1,763) — exercise price 13.90
Disposed (D)1,763——0Direct (D) No
F3
  • F3 Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration.
Open filing 0001104659-26-012188 Read from the filing’s XML Dispute this row
2026-02-09 Filed 2026-02-09Stehman-Breen Catherine Director
U

Disposition pursuant to a tender of shares in a change of control transaction

Common Stock
Disposed (D)4,752——0Direct (D) No
F1, F2
  • F1 Pursuant to the terms of that certain Agreement and Plan of Merger (the Merger Agreement), by and among Generation Bio. Co. (the Issuer), XOMA Royalty Corporation (Parent) and Parent's wholly-owned subsidiary, XRA 7 Corp. (Merger Sub), dated as of December 15, 2025, the shares (the Shares) of common stock, par value $0.0001 per share, of the Issuer (the Common Stock) that were tendered to Merger Sub prior to the expiration time of the offer were exchanged for (i) a purchase price of $4.2913 per Share to the stockholders in cash, without interest and less any applicable tax withholding (the Cash Amount), plus (ii) one non-tradeable contingent value right per Share (the CVR),
  • F2 (continued from footnote 1) which represents the right to receive certain contingent payments in cash in accordance with the terms and subject to the conditions of a contingent value rights agreement entered into by Parent and the rights agent, with an estimated maximum contingent consideration amount of $25.01 per CVR (the Cash Amount plus one CVR, collectively, the Offer Price). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Merger Sub merged with and into the Issuer, effective as of February 9, 2026 (the Effective Time), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent.
Open filing 0001104659-26-012197 Read from the filing’s XML Dispute this row
2026-02-09 Filed 2026-02-09Stehman-Breen Catherine Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (right to buy) — underlying Common Stock (3,000) — exercise price 3.874
Disposed (D)3,000——0Direct (D) No
F3
  • F3 Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock (Issuer Option) that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was less than the Cash Amount (each, an In-The-Money Option), became fully vested and was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product obtained by multiplying (x) the excess of the Cash Amount over the exercise price per share of Common Stock underlying such In-the-Money Option at the Effective Time by (y) the number of shares of Common Stock underlying such In-the-Money Option at the Effective Time.
Open filing 0001104659-26-012197 Read from the filing’s XML Dispute this row
2026-02-09 Filed 2026-02-09Stehman-Breen Catherine Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (right to buy) — underlying Common Stock (5,200) — exercise price 190.00
Disposed (D)5,200——0Direct (D) No
F4
  • F4 Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration.
Open filing 0001104659-26-012197 Read from the filing’s XML Dispute this row
2026-02-09 Filed 2026-02-09Stehman-Breen Catherine Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (right to buy) — underlying Common Stock (1,500) — exercise price 265.90
Disposed (D)1,500——0Direct (D) No
F4
  • F4 Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration.
Open filing 0001104659-26-012197 Read from the filing’s XML Dispute this row
2026-02-09 Filed 2026-02-09Stehman-Breen Catherine Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (right to buy) — underlying Common Stock (1,920) — exercise price 61.90
Disposed (D)1,920——0Direct (D) No
F4
  • F4 Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration.
Open filing 0001104659-26-012197 Read from the filing’s XML Dispute this row
2026-02-09 Filed 2026-02-09Stehman-Breen Catherine Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (right to buy) — underlying Common Stock (2,500) — exercise price 48.30
Disposed (D)2,500——0Direct (D) No
F4
  • F4 Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration.
Open filing 0001104659-26-012197 Read from the filing’s XML Dispute this row
2026-02-09 Filed 2026-02-09Stehman-Breen Catherine Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (right to buy) — underlying Common Stock (6,000) — exercise price 33.20
Disposed (D)6,000——0Direct (D) No
F4
  • F4 Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration.
Open filing 0001104659-26-012197 Read from the filing’s XML Dispute this row
2026-02-09 Filed 2026-02-09Rhodes Jason P Director
U

Disposition pursuant to a tender of shares in a change of control transaction

Common Stock
Disposed (D)711,193——0Indirect (I) See FootnoteNo
F1, F2, F3
  • F1 Pursuant to the terms of that certain Agreement and Plan of Merger (the Merger Agreement), by and among Generation Bio. Co. (the Issuer), XOMA Royalty Corporation (Parent) and Parent's wholly-owned subsidiary, XRA 7 Corp. (Merger Sub), dated as of December 15, 2025, the shares (the Shares) of common stock, par value $0.0001 per share, of the Issuer (the Common Stock) that were tendered to Merger Sub prior to the expiration time of the offer were exchanged for (i) a purchase price of $4.2913 per Share to the stockholders in cash, without interest and less any applicable tax withholding (the Cash Amount), plus (ii) one non-tradeable contingent value right per Share (the CVR),
  • F2 (continued from footnote 1) which represents the right to receive certain contingent payments in cash in accordance with the terms and subject to the conditions of a contingent value rights agreement entered into by Parent and the rights agent, with an estimated maximum contingent consideration amount of $25.01 per CVR (the Cash Amount plus one CVR, collectively, the Offer Price). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Merger Sub merged with and into the Issuer, effective as of February 9, 2026 (the Effective Time), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent.
  • F3 The shares are held directly by Atlas Venture Fund X, L.P. (Atlas Venture Fund X). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. (AVA X LP). Atlas Venture Associates X, LLC (AVA X LLC) is the general partner of AVA X LP. The Reporting Person is a member of AVA X LLC and disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of his pecuniary interest therein, if any.
Open filing 0001104659-26-012195 Read from the filing’s XML Dispute this row
2026-02-09 Filed 2026-02-09Rhodes Jason P Director
U

Disposition pursuant to a tender of shares in a change of control transaction

Common Stock
Disposed (D)116,693——0Indirect (I) See FootnoteNo
F1, F2, F4
  • F1 Pursuant to the terms of that certain Agreement and Plan of Merger (the Merger Agreement), by and among Generation Bio. Co. (the Issuer), XOMA Royalty Corporation (Parent) and Parent's wholly-owned subsidiary, XRA 7 Corp. (Merger Sub), dated as of December 15, 2025, the shares (the Shares) of common stock, par value $0.0001 per share, of the Issuer (the Common Stock) that were tendered to Merger Sub prior to the expiration time of the offer were exchanged for (i) a purchase price of $4.2913 per Share to the stockholders in cash, without interest and less any applicable tax withholding (the Cash Amount), plus (ii) one non-tradeable contingent value right per Share (the CVR),
  • F2 (continued from footnote 1) which represents the right to receive certain contingent payments in cash in accordance with the terms and subject to the conditions of a contingent value rights agreement entered into by Parent and the rights agent, with an estimated maximum contingent consideration amount of $25.01 per CVR (the Cash Amount plus one CVR, collectively, the Offer Price). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Merger Sub merged with and into the Issuer, effective as of February 9, 2026 (the Effective Time), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent.
  • F4 The shares are owned directly by Atlas Venture Opportunity Fund I, L.P. (AVOF I). Atlas Venture Associates Opportunity I, L.P. (AVAO LP) is the general partner of AVOF I. Atlas Venture Associates Opportunity I, LLC (AVAO LLC) is the general partner of AVAO LP. The Reporting Person is a member of AVAO LLC and disclaims Section 16 beneficial ownership of the securities held by AVOF I, except to the extent of his pecuniary interest therein, if any.
Open filing 0001104659-26-012195 Read from the filing’s XML Dispute this row
2026-02-09 Filed 2026-02-09Rhodes Jason P Director
U

Disposition pursuant to a tender of shares in a change of control transaction

Common Stock
Disposed (D)60——0Indirect (I) See FootnoteNo
F1, F2, F5
  • F1 Pursuant to the terms of that certain Agreement and Plan of Merger (the Merger Agreement), by and among Generation Bio. Co. (the Issuer), XOMA Royalty Corporation (Parent) and Parent's wholly-owned subsidiary, XRA 7 Corp. (Merger Sub), dated as of December 15, 2025, the shares (the Shares) of common stock, par value $0.0001 per share, of the Issuer (the Common Stock) that were tendered to Merger Sub prior to the expiration time of the offer were exchanged for (i) a purchase price of $4.2913 per Share to the stockholders in cash, without interest and less any applicable tax withholding (the Cash Amount), plus (ii) one non-tradeable contingent value right per Share (the CVR),
  • F2 (continued from footnote 1) which represents the right to receive certain contingent payments in cash in accordance with the terms and subject to the conditions of a contingent value rights agreement entered into by Parent and the rights agent, with an estimated maximum contingent consideration amount of $25.01 per CVR (the Cash Amount plus one CVR, collectively, the Offer Price). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Merger Sub merged with and into the Issuer, effective as of February 9, 2026 (the Effective Time), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent.
  • F5 The shares are held directly by Atlas Venture Associates Opportunity I, L.P. (AVAO LP). Atlas Venture Associates Opportunity I, LLC (AVAO LLC) is the general partner of AVAO LP. The Reporting Person is a member of AVAO LLC and disclaims Section 16 beneficial ownership of the securities held by AVAO LP, except to the extent of his pecuniary interest therein, if any.
Open filing 0001104659-26-012195 Read from the filing’s XML Dispute this row
2026-02-09 Filed 2026-02-09Rhodes Jason P Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (right to buy) — underlying Common Stock (3,000) — exercise price 3.874
Disposed (D)3,000——0Direct (D) No
F6
  • F6 Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock (Issuer Option) that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was less than the Cash Amount (each, an In-The-Money Option), became fully vested and was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product obtained by multiplying (x) the excess of the Cash Amount over the exercise price per share of Common Stock underlying such In-the-Money Option at the Effective Time by (y) the number of shares of Common Stock underlying such In-the-Money Option at the Effective Time.
Open filing 0001104659-26-012195 Read from the filing’s XML Dispute this row
2026-02-09 Filed 2026-02-09Rhodes Jason P Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (right to buy) — underlying Common Stock (5,200) — exercise price 190.00
Disposed (D)5,200——0Direct (D) No
F7
  • F7 Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration.
Open filing 0001104659-26-012195 Read from the filing’s XML Dispute this row
2026-02-09 Filed 2026-02-09Rhodes Jason P Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (right to buy) — underlying Common Stock (1,500) — exercise price 265.90
Disposed (D)1,500——0Direct (D) No
F7
  • F7 Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration.
Open filing 0001104659-26-012195 Read from the filing’s XML Dispute this row
2026-02-09 Filed 2026-02-09Rhodes Jason P Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (right to buy) — underlying Common Stock (1,920) — exercise price 61.90
Disposed (D)1,920——0Direct (D) No
F7
  • F7 Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration.
Open filing 0001104659-26-012195 Read from the filing’s XML Dispute this row
2026-02-09 Filed 2026-02-09Rhodes Jason P Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (right to buy) — underlying Common Stock (2,500) — exercise price 48.30
Disposed (D)2,500——0Direct (D) No
F7
  • F7 Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration.
Open filing 0001104659-26-012195 Read from the filing’s XML Dispute this row
2026-02-09 Filed 2026-02-09Rhodes Jason P Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (right to buy) — underlying Common Stock (6,000) — exercise price 33.20
Disposed (D)6,000——0Direct (D) No
F7
  • F7 Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration.
Open filing 0001104659-26-012195 Read from the filing’s XML Dispute this row
2026-02-09 Filed 2026-02-09Atlas Venture Fund X, L.P. 10% ownerATLAS VENTURE ASSOCIATES X, L.P. 10% ownerAtlas Venture Associates X, LLC 10% ownerAtlas Venture Opportunity Fund I, L.P. 10% ownerAtlas Venture Associates Opportunity I, L.P. 10% ownerAtlas Venture Associates Opportunity I, LLC 10% owner
U

Disposition pursuant to a tender of shares in a change of control transaction

Common Stock
Disposed (D)711,193——0Direct (D) No
F1, F2, F3
  • F1 Pursuant to the terms of that certain Agreement and Plan of Merger (the Merger Agreement), by and among Generation Bio. Co. (the Issuer), XOMA Royalty Corporation (Parent) and Parent's wholly-owned subsidiary, XRA 7 Corp. (Merger Sub), dated as of December 15, 2025, the shares (the Shares) of common stock, par value $0.0001 per share, of the Issuer (the Common Stock) that were tendered to Merger Sub prior to the expiration time of the offer were exchanged for (i) a purchase price of $4.2913 per Share to the stockholders in cash, without interest and less any applicable tax withholding (the Cash Amount), plus (ii) one non-tradeable contingent value right per Share (the CVR),
  • F2 (continued from footnote 1) which represents the right to receive certain contingent payments in cash in accordance with the terms and subject to the conditions of a contingent value rights agreement entered into by Parent and the rights agent, with an estimated maximum contingent consideration amount of $25.01 per CVR (the Cash Amount plus one CVR, collectively, the Offer Price). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Merger Sub merged with and into the Issuer, effective as of February 9, 2026 (the Effective Time), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent.
  • F3 The shares are held directly by Atlas Venture Fund X, L.P. (Atlas Venture Fund X). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. (AVA X LP). Atlas Venture Associates X, LLC (AVA X LLC) is the general partner of AVA X LP. Each of AVA X LP and AVA X LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of its pecuniary interest therein, if any.
Open filing 0001231919-26-000124 Read from the filing’s XML Dispute this row
2026-02-09 Filed 2026-02-09Atlas Venture Fund X, L.P. 10% ownerATLAS VENTURE ASSOCIATES X, L.P. 10% ownerAtlas Venture Associates X, LLC 10% ownerAtlas Venture Opportunity Fund I, L.P. 10% ownerAtlas Venture Associates Opportunity I, L.P. 10% ownerAtlas Venture Associates Opportunity I, LLC 10% owner
U

Disposition pursuant to a tender of shares in a change of control transaction

Common Stock
Disposed (D)116,693——0Indirect (I) See footnoteNo
F1, F2, F4
  • F1 Pursuant to the terms of that certain Agreement and Plan of Merger (the Merger Agreement), by and among Generation Bio. Co. (the Issuer), XOMA Royalty Corporation (Parent) and Parent's wholly-owned subsidiary, XRA 7 Corp. (Merger Sub), dated as of December 15, 2025, the shares (the Shares) of common stock, par value $0.0001 per share, of the Issuer (the Common Stock) that were tendered to Merger Sub prior to the expiration time of the offer were exchanged for (i) a purchase price of $4.2913 per Share to the stockholders in cash, without interest and less any applicable tax withholding (the Cash Amount), plus (ii) one non-tradeable contingent value right per Share (the CVR),
  • F2 (continued from footnote 1) which represents the right to receive certain contingent payments in cash in accordance with the terms and subject to the conditions of a contingent value rights agreement entered into by Parent and the rights agent, with an estimated maximum contingent consideration amount of $25.01 per CVR (the Cash Amount plus one CVR, collectively, the Offer Price). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Merger Sub merged with and into the Issuer, effective as of February 9, 2026 (the Effective Time), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent.
  • F4 The shares are held directly by Atlas Venture Opportunity Fund I, L.P. (Atlas Venture Opportunity Fund I). The general partner of Atlas Venture Opportunity Fund I is Atlas Venture Associates Opportunity I, LP (AVAO I LP). Atlas Venture Associates Opportunity I, LLC (AVAO I LLC) is the general partner of AVAO I LP. Each of AVAO I LP and AVAO I LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Opportunity Fund I, except to the extent of its pecuniary interest therein, if any.
Open filing 0001231919-26-000124 Read from the filing’s XML Dispute this row
2026-02-09 Filed 2026-02-09Atlas Venture Fund X, L.P. 10% ownerATLAS VENTURE ASSOCIATES X, L.P. 10% ownerAtlas Venture Associates X, LLC 10% ownerAtlas Venture Opportunity Fund I, L.P. 10% ownerAtlas Venture Associates Opportunity I, L.P. 10% ownerAtlas Venture Associates Opportunity I, LLC 10% owner
U

Disposition pursuant to a tender of shares in a change of control transaction

Common Stock
Disposed (D)60——0Indirect (I) See footnoteNo
F1, F2, F5
  • F1 Pursuant to the terms of that certain Agreement and Plan of Merger (the Merger Agreement), by and among Generation Bio. Co. (the Issuer), XOMA Royalty Corporation (Parent) and Parent's wholly-owned subsidiary, XRA 7 Corp. (Merger Sub), dated as of December 15, 2025, the shares (the Shares) of common stock, par value $0.0001 per share, of the Issuer (the Common Stock) that were tendered to Merger Sub prior to the expiration time of the offer were exchanged for (i) a purchase price of $4.2913 per Share to the stockholders in cash, without interest and less any applicable tax withholding (the Cash Amount), plus (ii) one non-tradeable contingent value right per Share (the CVR),
  • F2 (continued from footnote 1) which represents the right to receive certain contingent payments in cash in accordance with the terms and subject to the conditions of a contingent value rights agreement entered into by Parent and the rights agent, with an estimated maximum contingent consideration amount of $25.01 per CVR (the Cash Amount plus one CVR, collectively, the Offer Price). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Merger Sub merged with and into the Issuer, effective as of February 9, 2026 (the Effective Time), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent.
  • F5 The shares are held directly by AVAO I LP. AVAO I LLC is the general partner of AVAO I LP. AVAO I LLC disclaims Section 16 beneficial ownership of the securities held by AVAO I LP except to the extent of its pecuniary interest therein, if any.
Open filing 0001231919-26-000124 Read from the filing’s XML Dispute this row
2026-02-09 Filed 2026-02-09Quinn Anthony G. Director
U

Disposition pursuant to a tender of shares in a change of control transaction

Common Stock
Disposed (D)29,928——0Direct (D) No
F1, F2
  • F1 Pursuant to the terms of that certain Agreement and Plan of Merger (the Merger Agreement), by and among Generation Bio. Co. (the Issuer), XOMA Royalty Corporation (Parent) and Parent's wholly-owned subsidiary, XRA 7 Corp. (Merger Sub), dated as of December 15, 2025, the shares (the Shares) of common stock, par value $0.0001 per share, of the Issuer (the Common Stock) that were tendered to Merger Sub prior to the expiration time of the offer were exchanged for (i) a purchase price of $4.2913 per Share to the stockholders in cash, without interest and less any applicable tax withholding (the Cash Amount), plus (ii) one non-tradeable contingent value right per Share (the CVR),
  • F2 (continued from footnote 1) which represents the right to receive certain contingent payments in cash in accordance with the terms and subject to the conditions of a contingent value rights agreement entered into by Parent and the rights agent, with an estimated maximum contingent consideration amount of $25.01 per CVR (the Cash Amount plus one CVR, collectively, the Offer Price). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Merger Sub merged with and into the Issuer, effective as of February 9, 2026 (the Effective Time), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent.
Open filing 0001104659-26-012194 Read from the filing’s XML Dispute this row
2026-02-09 Filed 2026-02-09Quinn Anthony G. Director
U

Disposition pursuant to a tender of shares in a change of control transaction

Common Stock
Disposed (D)7,283——0Indirect (I) By Quinn Family Irrevocable Trust of 2021No
F1, F2, F3
  • F1 Pursuant to the terms of that certain Agreement and Plan of Merger (the Merger Agreement), by and among Generation Bio. Co. (the Issuer), XOMA Royalty Corporation (Parent) and Parent's wholly-owned subsidiary, XRA 7 Corp. (Merger Sub), dated as of December 15, 2025, the shares (the Shares) of common stock, par value $0.0001 per share, of the Issuer (the Common Stock) that were tendered to Merger Sub prior to the expiration time of the offer were exchanged for (i) a purchase price of $4.2913 per Share to the stockholders in cash, without interest and less any applicable tax withholding (the Cash Amount), plus (ii) one non-tradeable contingent value right per Share (the CVR),
  • F2 (continued from footnote 1) which represents the right to receive certain contingent payments in cash in accordance with the terms and subject to the conditions of a contingent value rights agreement entered into by Parent and the rights agent, with an estimated maximum contingent consideration amount of $25.01 per CVR (the Cash Amount plus one CVR, collectively, the Offer Price). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Merger Sub merged with and into the Issuer, effective as of February 9, 2026 (the Effective Time), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent.
  • F3 The securities are directly held by the Quinn Family Irrevocable Trust of 2021 (the Quinn Family Trust), formerly the Spousal Lifetime Access Trust. Anthony G. Quinn is the settlor of the Quinn Family Trust, M. Clare Quinn is the trustee for the Quinn Family Trust and the Quinn Family Trust is for the benefit of M. Clare Quinn, Emma, Richard, and Charles Quinn.
Open filing 0001104659-26-012194 Read from the filing’s XML Dispute this row
2026-02-09 Filed 2026-02-09Quinn Anthony G. Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (right to buy) — underlying Common Stock (3,000) — exercise price 3.874
Disposed (D)3,000——0Direct (D) No
F4
  • F4 Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock (Issuer Option) that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was less than the Cash Amount (each, an In-The-Money Option), became fully vested and was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product obtained by multiplying (x) the excess of the Cash Amount over the exercise price per share of Common Stock underlying such In-the-Money Option at the Effective Time by (y) the number of shares of Common Stock underlying such In-the-Money Option at the Effective Time.
Open filing 0001104659-26-012194 Read from the filing’s XML Dispute this row
2026-02-09 Filed 2026-02-09Quinn Anthony G. Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (right to buy) — underlying Common Stock (5,200) — exercise price 190.00
Disposed (D)5,200——0Direct (D) No
F5
  • F5 Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration.
Open filing 0001104659-26-012194 Read from the filing’s XML Dispute this row
2026-02-09 Filed 2026-02-09Quinn Anthony G. Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (right to buy) — underlying Common Stock (1,500) — exercise price 265.90
Disposed (D)1,500——0Direct (D) No
F5
  • F5 Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration.
Open filing 0001104659-26-012194 Read from the filing’s XML Dispute this row

Institutional holders (Form 13F)

No Form 13F position in this issuer is placed in the store. A holder not yet linked or not yet filed is absent, not zero.

Trades by members of Congress

Periodic transaction reports filed by U.S. House members that name this company’s stock. Dates and amounts are as filed.

No House member’s trade in this company is placed in the store. A trade not yet filed or not linked to a company is absent, not zero.

5% holders (Schedule 13D and 13G)

Schedules filed in the SEC’s structured format (late 2024 onward) are read here. Earlier schedules are free text and are not read.

5% holders, newest event first, as filed
HolderPercent of classShares heldEvent dateFormSource
Atlas Venture Fund X, L.P. COMMON STOCK, $0.0001 PAR VALUE0.00.0003/31/2026 Filed 2026-05-14SCHEDULE 13G/AAmendment 3Open filing 0001628098-26-000003 Dispute this row
ATLAS VENTURE ASSOCIATES X, L.P. COMMON STOCK, $0.0001 PAR VALUE0.00.0003/31/2026 Filed 2026-05-14SCHEDULE 13G/AAmendment 3Open filing 0001628098-26-000003 Dispute this row
Atlas Venture Associates X, LLC COMMON STOCK, $0.0001 PAR VALUE0.00.0003/31/2026 Filed 2026-05-14SCHEDULE 13G/AAmendment 3Open filing 0001628098-26-000003 Dispute this row
Atlas Venture Opportunity Fund I, L.P. COMMON STOCK, $0.0001 PAR VALUE0.00.0003/31/2026 Filed 2026-05-14SCHEDULE 13G/AAmendment 3Open filing 0001628098-26-000003 Dispute this row
Atlas Venture Associates Opportunity I, L.P. COMMON STOCK, $0.0001 PAR VALUE0.00.0003/31/2026 Filed 2026-05-14SCHEDULE 13G/AAmendment 3Open filing 0001628098-26-000003 Dispute this row
Atlas Venture Associates Opportunity I, LLC COMMON STOCK, $0.0001 PAR VALUE0.00.0003/31/2026 Filed 2026-05-14SCHEDULE 13G/AAmendment 3Open filing 0001628098-26-000003 Dispute this row
Baselake Partners, LP Common Stock, $0.0001 Par Value0002/09/2026 Filed 2026-02-11SCHEDULE 13G/AAmendment 1Open filing 0001957912-26-000011 Dispute this row
Baselake Management, LLC Common Stock, $0.0001 Par Value0002/09/2026 Filed 2026-02-11SCHEDULE 13G/AAmendment 1Open filing 0001957912-26-000011 Dispute this row
David Paolella Common Stock, $0.0001 Par Value0002/09/2026 Filed 2026-02-11SCHEDULE 13G/AAmendment 1Open filing 0001957912-26-000011 Dispute this row
Baselake Partners, LP Common Stock, $0.0001 Par Value5.2350,00002/05/2026 Filed 2026-02-06SCHEDULE 13GOpen filing 0001957912-26-000009 Dispute this row
Baselake Management, LLC Common Stock, $0.0001 Par Value5.2350,00002/05/2026 Filed 2026-02-06SCHEDULE 13GOpen filing 0001957912-26-000009 Dispute this row
David Paolella Common Stock, $0.0001 Par Value5.2350,00002/05/2026 Filed 2026-02-06SCHEDULE 13GOpen filing 0001957912-26-000009 Dispute this row
T. Rowe Price Associates, Inc. COMMON STOCK3.1209,64112/31/2025 Filed 2026-02-17SCHEDULE 13G/AAmendment 8Open filing 0000080255-26-000277 Dispute this row
Renaissance Technologies LLC Common Stock, $0.0001 Par Value4.27287,61412/31/2025 Filed 2026-02-12SCHEDULE 13G/AAmendment 1Open filing 0001037389-26-000010 Dispute this row
Renaissance Technologies Holdings Corporation Common Stock, $0.0001 Par Value4.27287,61412/31/2025 Filed 2026-02-12SCHEDULE 13G/AAmendment 1Open filing 0001037389-26-000010 Dispute this row
SymBiosis Capital Partners, LLC Common Stock6.3421,926.0009/30/2025 Filed 2025-11-14SCHEDULE 13GOpen filing 0002006045-25-000003 Dispute this row
SymBiosis Capital Partners, LLC Common Stock6.3421,926.0009/30/2025 Filed 2025-11-14SCHEDULE 13G/AAmendment 1Open filing 0002006045-25-000004 Dispute this row
T. Rowe Price Associates, Inc. COMMON STOCK8.6576,78909/30/2025 Filed 2025-11-14SCHEDULE 13G/AAmendment 7Open filing 0000080255-25-000831 Dispute this row
Renaissance Technologies LLC Common Stock, $0.0001 Par Value5.11344,26307/01/2025 Filed 2025-11-13SCHEDULE 13GOpen filing 0001037389-25-000072 Dispute this row
Renaissance Technologies Holdings Corporation Common Stock, $0.0001 Par Value5.11344,26307/01/2025 Filed 2025-11-13SCHEDULE 13GOpen filing 0001037389-25-000072 Dispute this row
T. Rowe Price Associates, Inc. COMMON STOCK12.68,462,61106/30/2025 Filed 2025-08-14SCHEDULE 13G/AAmendment 6Open filing 0000080255-25-000602 Dispute this row
FMR LLC #OTHER3.52,345,624.0006/30/2025 Filed 2025-08-06SCHEDULE 13G/AAmendment 7Open filing 0000315066-25-002036 Dispute this row
Abigail P. Johnson #OTHER3.52,345,624.0006/30/2025 Filed 2025-08-06SCHEDULE 13G/AAmendment 7Open filing 0000315066-25-002036 Dispute this row
BlackRock, Inc. Common Stock1.71,152,04706/30/2025 Filed 2025-07-17SCHEDULE 13G/AAmendment 1Open filing 0002052113-25-003054 Dispute this row

Percent is of the class the filing names, as the holder stated it. Members of a group each report the group’s shares, so rows are not added together.

What was read

2,676,809 filings read, dated 2004-06-14 to 2026-11-19: Forms 3, 3/A, 4, 4/A, 5, 5/A.

Years can be incomplete while the archive is still being read. A year with few filings here is not a statement that few were made.

Filings read, by filing year
Filing yearFilings read
201593,896
2016222,642
2017222,009
2018223,345
2019216,482
2020226,343
2021249,835
2022231,682
2023229,674
2024234,045
2025235,520
2026263,123

Filings made before the SEC required XML are listed, not extracted.

Back to GENERATION BIO CO.